The rapid advancement of precision medicines (PMs) over the past decade has reshaped modern healthcare, but it has also introduced significant challenges for health systems. Unlike conventional therapies, many PMs lack the robust evidence necessary for confident assessments, creating uncertainty for Health Technology Assessment (HTA) agencies to make confident decisions about value, affordability, and reimbursement.

This paper examines the current landscape of PMs across the Asia-Pacific region and identifies the key challenges and opportunities for HTA systems. It draws on two main sources: (1) a targeted literature review of economic evaluations (EEs) of to identify emerging assessment methods and reimbursement models, and (2) a regional survey of HTA agencies from 12 of 20 invited countries, offering insights into their experiences and perspectives on PMs.